Ablynx N.V.

How companies can build value and climb market cap tiers to reach the top

Plus: AZ cuts late-stage GLP-1, Wilson’s disease programs and updates from Sanofi, 4D Molecular, Generate

Plus: Flamingo hires a new CMO, and updates from Arkuda and GeneDx

NIH spinout hands off rights to RNA therapy as head and neck cancer program moves toward clinic

Australian-German newco is delivering antibody therapies inside liver cells by encoding them as mRNA

Plus Viz.ai raises $100 M, MoonLake debuts on NASDAQ, and updates from

Dutch start-up with about €40M in funding will advance fusion protein targeting von Willebrand factor for two indications

Building on prior deal around hepatic platform, takeout gives Novo broader access to Dicerna’s technology

Awaiting a SPAC, the Swiss company thinks it can bring more efficacy, safety to IL-17-driven diseases

Clinical bispecific programs now span four disease areas outside of cancer